Science News: ESC 2014 : Sunday

Updated:Oct 30,2014

SCIENCE NEWS - covering the science presented daily at ESC Congress 2014 with video highlights, summary slides for late-breaking clinical trials presented in Hot Line sessions, and links to AHA science and resources related to the Hot Line science each day.

HOT LINE I — CARDIOVASCULAR DISEASE: NOVEL THERAPIES
Elliott Antman, MD, FAHA, and Mariell Jessup, MD, FAHA Elliott Antman, MD, FAHA, Mariell Jessup, MD, FAHA, and Mark Creager, MD, FAHA
PARADIGM-HF (PDF) | See more in-depth analysis on this trial
Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial
 
NECTAR-HF (PDF)
A randomized controlled trial of vagal stimulation for the treatment of systolic heart failure: NEural Cardiac TherApy foR Heart Failure
 
CONFIRM-HF (PDF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency
 
MORE-CRT (PDF)
Cardiac resynchronization therapy with a novel quadripolar lead decreases complications at six months: preliminary results
 
POPE 2 (PDF)
Colchicine for Post- operative Pericardial Effusion: The post-operative pericardial effusion study. A multicenter, double-blind, randomized trial
 
COPPS 2 (PDF)
COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation
 

HOT LINE II — CORONARY ARTERY DISEASE AND LIPIDS
Elliott Antman, MD, FAHA,
Mariell Jessup,
MD, FAHA,
SOLID-TIMI 52 (PDF)
The Stabilization Of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction 52 trial: Primary Results
 
SIGNIFY (PDF)
Ivabradine in patients with stable coronary artery disease without clinical heart failure
 
ODYSSEY COMBO II (PDF)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin
 
ODYSSEY FH I & FH II (PDF)
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy
 
ODYSSEY LONG TERM (PDF)
Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from 2,341 patients.
 
LISTEN (PDF)
The differences of the effects on lipid-lowering actions and glucose metabolisms between rosuvastatin and atorvastatin in Japanese diabetic patients with hyperlipidemia.
 


Heart Failure Resource Center: providing patients and healthcare providers one convenient place to understand, prevent and treat heart failure.


Related Science
Resources for your Practice
Resources for your Practice & Patients
Additional Links: